Aurelia Bioscience is a pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening.
We work in early stages of the drug discovery pipeline including target identification and validation, hit identification, hit to lead as well as lead identification and optimisation. We have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner.
Our PhD and pharma trained scientists have decades of experience in pre-clinical discovery, designing and developing low, medium and high throughput assays for hits-to-lead, lead identification and lead optimisation drug discovery phases. This allows us to identify the biological screening techniques and technologies most suited to our clients and avoids the pursuit of expensive and time consuming approaches unsuited to the particular piece of work or project. To this end, Aurelia Bioscience has built a laboratory platform using state-of-the-art technologies that deliver a range of technical approaches, each with its own unique set of characteristics that lend themselves to certain biology. Our appreciation of the complexity of drug discovery programmes allows us to understand the requirements of our clients in the context of the larger picture and the need for synchronisation and involvement with other disciplines.
Phone: 0115 837 0503
Website: Aurelia Bioscience